Atrial Fibrillation
Read Time: 2 mins

49/Thromboprophylaxis in elderly atrial fibrillation patients with recent thromboembolism and at high bleeding risk: a report from the ChiOTEAF Registry

Copy Link
Published Online: Sep 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr49
Authors: Y Guo (Presenting Author) - Medical School of Chinese PLA, Department of Cardiology, Chinese PLA General Hospital, Beijing, China; Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom, Beijing; Y Wang - Chinese PLA General Hospital, Beijing; GYH Lip - Medical School of Chinese PLA, Department of Cardiology, Chinese PLA General; Hospital, Beijing, China; Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Quick Links:
Article Information

Background: Elderly patients with atrial fibrillation (AF) may present with acute thromboembolic events, often in combination with high bleeding risk. There are limited data on such high-risk patients from China, as well as the benefits and harms of oral anticoagulants (OAC).

Objective: To investigate the impacts on death, thromboembolism (TE), and acute coronary artery syndrome (ACS) of different antithrombotic treatment strategies in elderly patients with AF with recent acute thromboembolism and at high risk for bleeding.

Methods: Chinese Optimal Thrombophylaxis in the Elderly patients with Atrial Fibrillation (ChiOTEAF Registry) was a prospectively, real-world registry from 44 research centres across China between Oct 2014 to Dec 2018. A Cox proportional hazard model analysis was performed for the outcomes related to antithrombotic therapy.

Results: There were 1141 patients (mean age 77 (SD 9) years; 42.3% female) presenting with acute thromboembolism (521 ischaemic stroke, 86 systemic thromboembolism, 664 ACS; of these, 1018 sustained single TE, 116 dual TE events, and 7 triple TE) at enrolment, with follow-up (mean ± SD) of 369 (54) days. CHA2DS2-VASc and HAS-BLED scores (mean ± SD) were 4.5 ± 1.6, and 2.8 ± 1.1 in this population, respectively. Among these, there were 786 (68.9%) AF patients with bleeding events or receiving invasive procedure/ surgery during hospitalization. During one-year follow-up, there were 57 (5.0%) deaths, 31 (2.7%) thromboembolism, and 14 (1.2%) ACS, while there were 4 (0.4%) intracranial haemorrhage and 15 (1.3%) extracranial haemorrhage. The usage (n, %) of oral anticoagulants (OACs), parenteral anticoagulant, and antiplatelet at discharge were 434 (38.0%), 80 (7.0%), and 707 (62.0%), respectively. After adjusting for age, gender, heart failure, hypertension, diabetes mellitus, prior myocardial infarction, chronic renal dysfunction, liver dysfunction, OACs at discharge reduced the risk for all-cause death, thromboembolism, and ACS (hazard ratio, HR, 95% confidence interval, CI) for the whole cohort (HR, 95% CI, 0.43, 0.19-0.95, p=0.04 on warfarin; 0.42, 0.20-0.87, p=0.02 on non-vitamin K antagonist OACs, NOAC, respectively). Subgroup analyses showed that the decreased risks for all-cause death, thromboembolism, and ACS of OACs were in AF patients with acute ischaemic stroke (all p<0.05), but not in AF patients with ACS. For AF patients with bleeding events, or receiving invasive procedure/surgery during hospitalization, NOAC at discharge decreased the risk for all-cause death, thromboembolism, and ACS (HR, 95% CI, 0.28, 0.10-0.78, p= 0.01).

Conclusion: Elderly atrial fibrillation patients with recent thromboembolism and at high bleeding risk derive benefits from OACs at discharge, especially amongst those with recent ischaemic stroke and with NOAC use.

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72